Market news — every asset we track

Assets

IXHL

Incannex begins Phase 2 dosing study for sleep apnea drug

Sep 9Investing.com

IXHL

Incannex doses first patient in sleep apnea drug trial

Aug 25Investing.com

IXHL

Incannex Announces First Patient Dosed in DReAMzz Phase 2 Study of IHL-42X

First patient dosing represents another major clinical milestone for IHL-42X, building on positive Phase 2 RePOSA results demonstrating reductions in AHI...

Aug 25Barchart.com

IXHL

Incannex Secures A$5.1M R&D Tax Incentive Refund

Detailed price information for Incannex Healthcare Inc ADR (IXHL-Q) from The Globe and Mail including charting and trades.

Aug 12The Globe and Mail

IXHL

Incannex receives final A$5.1m R&D tax incentive refund

Aug 11Investing.com

IXHL

Incannex Commences Participant Screening in DReAMzz Phase 2 Study of IHL-42X for Obstructive Sleep Apnea

MELBOURNE, Australia and NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical company developing innovative therapies for high-impact indications,...

Jul 23Barchart.com

IXHL

Incannex (IXHL) Secures U.S. Patent Grant in Obstructive Sleep Apnea for IHL-42X

Incannex Healthcare Inc. (NASDAQ:IXHL) is one of the best strong buy penny stocks to invest in now. Incannex Healthcare Inc. (NASDAQ:IXHL) announced on June 25 the granting of a key patent by the United States Patent and Trademark Office (USPTO) titled “Compositions and Methods of Treatment for Obstructive Sleep Apnea.” Management stated that the granted patent […]

Jul 15Yahoo Finance

IXHL

This is the newest page. Registered accounts read further back.